Skip to main content
Accolade, Inc. (ACCD)
NASDAQ: ACCD · Real-Time Price · USD
3.480
+0.160 (4.82%)
Dec 20, 2024, 4:00 PM EST - Market closed

Accolade Revenue

Accolade had revenue of $106.36M in the quarter ending August 31, 2024, with 9.80% growth. This brings the company's revenue in the last twelve months to $441.03M, up 16.04% year-over-year. In the fiscal year ending February 29, 2024, Accolade had annual revenue of $414.29M with 14.09% growth.

Revenue (ttm)
$441.03M
Revenue Growth
+16.04%
P/S Ratio
0.61
Revenue / Employee
$183,762
Employees
2,400
Market Cap
280.27M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Feb 29, 2024414.29M51.15M14.09%
Feb 28, 2023363.14M53.12M17.13%
Feb 28, 2022310.02M139.66M81.98%
Feb 28, 2021170.36M37.85M28.57%
Feb 29, 2020132.51M37.70M39.76%
Feb 28, 2019 Pro Pro Pro
Feb 28, 2018 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Amylyx Pharmaceuticals 196.49M
Zynex 193.67M
Vanda Pharmaceuticals 190.86M
AC Immune 48.51M
C4 Therapeutics 33.67M
ProQR Therapeutics 20.51M
aTyr Pharma 235.00K
4D Molecular Therapeutics 17.00K
Revenue Rankings

ACCD News

More News